Abstracts tagged "fibrosis"

Abstract Number: 1850 • 2016 ACR/ARHP Annual Meeting
Optimization of a Murine Model to Recapitulate Dermal and Pulmonary Features of SSc
Tomoya Watanabe¹, Tetsuya Nishimoto², Jonathan Heywood³, Stanley Hoffman⁴, Logan Mlakar⁴ and Carol A. Feghali-Bostwick⁵, ¹Rheumatology, Medical University of South Carolina, Charleston, SC, ²Department of Medicine, Medical University of South Carolina, Charleston, SC, ³Rheumataology, Medical University of South Carolina, Chareston, SC, ⁴Medical University of South Carolina, Charleston, SC, ⁵Medicine, Medical University of South Carolina, Charleston, SC
Background/Purpose: The murine bleomycin (BLM)-induced fibrosis model is the most widely used in systemic sclerosis (SSc) studies. Traditionally, daily subcutaneous injections of BLM for 4-6…
Abstract Number: 1852 • 2016 ACR/ARHP Annual Meeting
Decreased Expression of Sirtuin 7 By Lung Fibroblasts from Patients with Scleroderma Contributes to Elevated Collagen Production
Anne E. Wyman^1,2, Zahid Noor¹, Nevins W. Todd^1,2, Irina G. Luzina^1,2 and Sergei P. Atamas^1,2, ¹University of Maryland School of Medicine, Baltimore, MD, ²Baltimore VA Medical Center, Baltimore, MD
Background/Purpose: Pulmonary fibrosis is a severe complication of systemic sclerosis (SSc). Changes in the expression levels of sirtuins (SIRTs), a family of NAD+-dependent histone deacetylases,…
Abstract Number: 1859 • 2016 ACR/ARHP Annual Meeting
Fucosyltransferase-1 Mediated Fucosylation of TGF-βR1 Is Critical to TGF-β Signaling in Scleroderma and in Bleomycin-Induced Fibrosis
W. Alexander Stinson¹, Pei-Suen Tsou^1,2, Yuxuan Du³, Huadong Cui¹, Ellen Cealey³, Nicholas Lepore⁴, Ray A. Ohara¹, Gautam Edhayan¹, Sarah Arwani¹, Rachel Morgan¹, Dinesh Khanna^1,2, David A. Fox¹ and M. Asif Amin⁵, ¹Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²University of Michigan Scleroderma Program, Ann Arbor, MI, ³Rheumatology, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁴University of Michigan, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁵Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease characterized by systemic fibrosis. The dysregulation of transforming growth factor-β (TGF-β) signaling causes proliferation of myofibroblasts…
Abstract Number: 1860 • 2016 ACR/ARHP Annual Meeting
Activating Transcription Factor 3 – a New Linkage Between Vasculopathy and Organ Fibrosis in Systemic Sclerosis
Thomas Wohlfahrt¹, Alina Soare², Tatjana Mallano², Morgane Gourlaouen³, Stephen Moss³, Britta Maurer⁴, Oliver Distler⁴, Tsonwin Hai⁵, Georg Schett², Jörg Distler² and Andreas Ramming², ¹Department of Internal Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ³Institute of Ophthalmology, Department of Cell Biology, University College London, London, United Kingdom, ⁴Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁵Department of Molecular and Cellular Biochemistry, The Ohio State University, Colombus, OH
Background/Purpose: Since vascular manifestations such as Raynaud’s phenomenon and morphological changes on nailfold capillaroscopy often precede the onset of other clinical manifestations of systemic sclerosis…
Abstract Number: 1862 • 2016 ACR/ARHP Annual Meeting
Modelling Healthy and Scleroderma Fibrotic Skin in Vitro: Mechanical Stress Alters Macrophage Cytokine Expression and Triggers Signalling Via the Mechano-Sensing Transcription Factor Myocardin-Related Transcription Factor-a
Angela Tam¹, Shiwen Xu¹, Henry Lopez¹, Korsa Khan², Bahja Ahmed Abdi³, Henrique Rosario⁴, Nikita Arumalla², Mark Gibson², Christopher Denton², David Abraham², Barbara D Smith⁵ and Richard J Stratton², ¹Division of Medicine, Centre for Rheumatology and Connective tissue disease, University College London, London, United Kingdom, ²Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ³Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ⁴Division of Medicine, Centre of Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ⁵Boston University School of Medicine, Boston, MA
Background/Purpose: Skin involvement is one of the most prominent clinical features in scleroderma. There is a marked contrast in mechanical stiffness between healthy forearm skin…
Abstract Number: 2068 • 2016 ACR/ARHP Annual Meeting
Type 2 Innate Lymphoid Cells – Cellular Source of Profibrotic Mediators Rapidly and Persistently Recruited in Experimental Fibrosis and Systemic Sclerosis
Stefanie Weber¹, Thomas Wohlfahrt¹, Simon Rauber¹, Markus Luber¹, Matthias Englbrecht², Clara Dees³, Christian Beyer⁴, Oliver Distler⁵, Georg Schett³, Joerg HW Distler³ and Andreas Ramming⁴, ¹Department of Internal Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3, Rheumatology & Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁴Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: We aimed to profile ILC2s in fibrotic tissues and to evaluate the functional impact of IC2s in the pathogenesis of systemic sclerosis (SSc). Methods:…
Abstract Number: 2069 • 2016 ACR/ARHP Annual Meeting
Dipeptidyl-Peptidase-4 (DPP4) Positive Fibroblast Subpopulation Promotes Fibrosis and Are a Molecular Target for Treatment of Fibrosis
Alina Soare^1,2, Simon Rauber³, Thomas Wohlfahrt¹, Clara Dees⁴, Ruifang Liang⁴, Yun Zhang¹, Chih-Wei Chen¹, Andreas Ramming⁵, Oliver Distler⁶, Carina Mihai⁷, Georg Schett⁴ and Joerg HW Distler⁴, ¹Department of Internal Medicine 3 and Institute for Clinical Immunology, Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Carol Davila University of Medicine and Pharmacy, Internal Medicine and Rheumatology Department, Cantacuzino Clinical Hospital, Bucharest, Romania, ³Department of Internal Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁵Department of Internal Medicine 3, Rheumatology and Immunology, Department of Internal Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁶Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁷Department of Internal Medicine and Rheumatology, Carol Davila University of Medicine and Pharmacy, Cantacuzino Hospital, Bucharest, Romania
Background/Purpose: Dipeptidyl-peptidase-4 (DPP4) has been recently shown to identify a distinct dermal lineage with intrinsic fibrogenic potential and its targeted inhibition leads to reduced scar…
Abstract Number: 2071 • 2016 ACR/ARHP Annual Meeting
Expression of Neuraminidase 1 (NEU1) Is Upregulated in the Lungs of Scleroderma Patients with Pulmonary Fibrosis, and Gene Delivery of NEU1 to Mouse Lungs Elicits Accumulation of CD8+ Lymphocytes and Collagen
Irina G. Luzina^1,2, Anne E. Wyman^1,2, Virginia Lockatell², Zahid Noor², Nevins W. Todd^1,2, Simeon E. Goldblum^1,2 and Sergei P. Atamas^1,2, ¹Baltimore VA Medical Center, Baltimore, MD, ²University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: We and others have previously reported that pulmonary fibrosis in patients with scleroderma is accompanied by pulmonary accumulation of predominantly CD8+ T lymphocytes. Earlier…
Abstract Number: 811 • 2016 ACR/ARHP Annual Meeting
Basophils Are Activated and Stimulate Both B Cells and Fibroblasts in Systemic Sclerosis
Benjamin Chaigne¹, Nicolas Dumoitier², Alexis Regent¹, Benjamin Terrier³, Jonathan London², Matthieu Groh¹, Nathalie Thieblemont⁴ and Luc Mouthon⁵, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ²INSERM U1016, Institut Cochin, Equipe Neutrophiles et Vascularites, Paris, France, ³Internal Medicine, Cochin Hospital, Paris, France, ⁴Inserm U1016, Paris, France, ⁵Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France
Background/Purpose: Systemic sclerosis (SSc) is a rare multisystem connective tissue disease characterized by skin and internal organs fibrosis and vascular abnormalities, along with the presence…
Abstract Number: 2355 • 2016 ACR/ARHP Annual Meeting
Histology of Bone Marrow Lesions in Osteoarthritis: A Systematic Literature Review
S. van Beest¹, F.P.B. Kroon¹, W. Damman¹, J.W. Schoones², A. Ioan-Facsinay¹ and M. Kloppenburg³, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Walaeus Library, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology and Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Bone marrow lesions (BMLs) are of high interest in osteoarthritis for their association with pain and structural progression. They are characterized on magnetic resonance…
Abstract Number: 812 • 2016 ACR/ARHP Annual Meeting
Monocytes/Neurotrophins/Myofibroblasts As a Novel Axis in Systemic Sclerosis
Michal Rudnik¹, Mara Stellato¹, Elena Pachera¹, Rucsandra Dobrota¹, Britta Maurer¹, Joerg C. Henes², Karin Klingel³, Karl Sotlar⁴, Przemyslaw Blyszczuk⁵, Oliver Distler¹ and Gabriela Kania¹, ¹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Department of Internal Medicine II, Division of Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, ³Department of Molecular Pathology, University Hospital Tuebingen, Tuebingen, Germany, ⁴Institute of Pathology, Ludwig Maximilians University, Munich, Germany, ⁵Cardioimmunology, Center of Molecular Cardiology, University of Zurich, 8952 Schlieren, Switzerland
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease, which is characterized by inflammation, fibrosis and vasculopathy in multiple organs, mainly in the lung, heart and…
Abstract Number: 2422 • 2016 ACR/ARHP Annual Meeting
Cyclic Amp, Erk5, and Transdifferentiation of Cardiac Fibroblasts in the Pathogenesis of Autoimmune Congenital Heart Block
Androo Markham¹, Sara Rasmussen², Miki Blumenberg³, Robert M Clancy² and Jill P. Buyon¹, ¹Medicine, New York University School of Medicine, New York, NY, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Dermatology, NYU School of Medicine, New York, NY
Background/Purpose: Maternal autoantibodies (Ab) reactive with the Ro/La ribonucleoprotein complex are associated with the development of cardiac injury in a fetus passively exposed to these…
Abstract Number: 823 • 2016 ACR/ARHP Annual Meeting
A Phase 2 Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness in Subjects with Systemic Sclerosis with Interstitial Lung Disease
Vivien Hsu¹, Christopher P.Denton², Robyn T. Domsic³, Daniel E. Furst⁴, Maureen Rischmueller⁵, Marina Stanislav⁶, Virginia D. Steen⁷, Douglas Hough⁸, Shimon Korish⁹, Alyse Cooper¹⁰, Peter H. Schafer¹¹ and Suktae Choi¹², ¹Rheumatology, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ, ²Centre of Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ³Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁵University of Adelaide, Adelaide, Australia, ⁶Research Rheumatology Institute n. a. V.A. Nassonova, Moscow, Russia, ⁷Rheumatology, Georgetown University Medical Center, Washington, DC, ⁸Clinical Research, Celgene Corporation, Warren, NJ, ⁹33 Technology Drive, Celgene Corporation, Warren, NJ, ¹⁰Immunology & Inflammation, Clinical Research, Celgene Corporation, Summit, NJ, ¹¹Department of Translational Development, Celgene Corporation, Summit, NJ, ¹²Biostatistics, Celgene Corporation, Summit, NJ
Background/Purpose: Pomalidomide (POM) is an IMiD compound, structurally similar to thalidomide. POM binds to cereblon and facilitates Ikaros and Aiolos degradation, resulting in immunomodulation of…
Abstract Number: 2507 • 2016 ACR/ARHP Annual Meeting
Assessment of Liver Fibrosis Using Transient Elastography in Patients with Rheumatoid Arthritis Exposed to Long Term Methotrexate
Min Kyung Chung¹, Seo Hwa Kim², Haneul Kim¹, Jung Hee Koh¹, Jennifer Lee³, Seung-Ki Kwok⁴, Ji Hyeon Ju⁵ and Sung-Hwan Park⁵, ¹Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of, ²Division of Rheumatology,, Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of, ⁴[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Methotrexate (MTX) has been recommended for the first line therapy of rheumatoid arthritis (RA), either alone or in combination with other DMARDs such as…
Abstract Number: 829 • 2016 ACR/ARHP Annual Meeting
High Level of Chemokine CCL2 Is Associated with Lung Fibrosis Progression and Reduced Survival in Two Independent Systemic Sclerosis Cohorts
Anna Hoffmann-Vold¹, Richard Huyen², Elizabeth R. Volkmann², Oyvind Midtvedt¹, Vyacheslav Palchevskiy², May Brit Lund³, Torhild Garen¹, Trond Mogens Aalokken⁴, Anders Heiervang Tennøe¹, Stephen Samuel Weigt², Mike Shino², Rajan Saggar⁵, David Ross², Joseph Lynch III², Thor Ueland⁶, Michael Fishbein⁷, Pål Aukrust⁸, Øyvind Molberg¹ and John A Belperio², ¹Rheumatology, Oslo University Hospital, Oslo, Norway, ²University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Respiratory Medicine, Oslo University Hospital, Oslo, Norway, ⁴Radiology, Oslo University Hospital, Oslo, Norway, ⁵Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁶Research, Oslo University Hospital, Oslo, Norway, ⁷Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA, ⁸Research Intitute for Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway
Background/Purpose: Markers for early identification of progressive interstitial lung disease (ILD) in systemic sclerosis (SSc) are in demand. The proto-typical inflammatory chemokine CCL2 has been linked…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].